These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 17850826)

  • 21. Long-term safety of cilostazol in patients with peripheral artery disease: the CASTLE study (Cilostazol: A Study in Long-term Effects).
    Hiatt WR; Money SR; Brass EP
    J Vasc Surg; 2008 Feb; 47(2):330-336. PubMed ID: 18155871
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of cilostazol in the treatment of intermittent claudication.
    Barnett AH; Bradbury AW; Brittenden J; Crichton B; Donnelly R; Homer-Vanniasinkam S; Mikhailidis DP; Stansby G
    Curr Med Res Opin; 2004 Oct; 20(10):1661-70. PubMed ID: 15462700
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of cilostazol on lipid and fatty acid metabolism.
    Nakamura N; Osawa H; Yamabe H; Okumura K; Hamazaki T
    Clin Exp Med; 2005 Mar; 4(4):170-3. PubMed ID: 15750763
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Management of peripheral arterial disease in the elderly: focus on cilostazol.
    Falconer TM; Eikelboom JW; Hankey GJ; Norman PE
    Clin Interv Aging; 2008; 3(1):17-23. PubMed ID: 18488875
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differential lipogenic effects of cilostazol and pentoxifylline in patients with intermittent claudication: potential role for interleukin-6.
    Lee TM; Su SF; Hwang JJ; Tseng CD; Chen MF; Lee YT; Wang SS
    Atherosclerosis; 2001 Oct; 158(2):471-6. PubMed ID: 11583728
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cilostazol: a new drug in the treatment intermittent claudication.
    Kumar M; Bhattacharya V
    Recent Pat Cardiovasc Drug Discov; 2007 Nov; 2(3):181-5. PubMed ID: 18221117
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The US experience with cilostazol in treating intermittent claudication.
    Hiatt WR
    Atheroscler Suppl; 2005 Dec; 6(4):21-31. PubMed ID: 16275166
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Type 3 phosphodiesterase inhibitors may be protective against cerebrovascular events in patients with claudication.
    Stone WM; Demaerschalk BM; Fowl RJ; Money SR
    J Stroke Cerebrovasc Dis; 2008; 17(3):129-33. PubMed ID: 18436153
    [TBL] [Abstract][Full Text] [Related]  

  • 29. L-Carnitine plus cilostazol versus cilostazol alone for the treatment of claudication in patients with peripheral artery disease: a multicenter, randomized, double-blind, placebo-controlled trial.
    Goldenberg NA; Krantz MJ; Hiatt WR
    Vasc Med; 2012 Jun; 17(3):145-54. PubMed ID: 22615190
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effects of cilostazol on exercise-induced ischaemia-reperfusion injury in patients with peripheral arterial disease.
    O'Donnell ME; Badger SA; Sharif MA; Makar RR; McEneny J; Young IS; Lee B; Soong CV
    Eur J Vasc Endovasc Surg; 2009 Mar; 37(3):326-35. PubMed ID: 19112032
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical manifestation of atherosclerotic peripheral arterial disease and the role of cilostazol in treatment of intermittent claudication.
    Grouse JR; Allan MC; Elam MB
    J Clin Pharmacol; 2002 Dec; 42(12):1291-8. PubMed ID: 12463722
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antiplatelet therapy using cilostazol, a specific PDE3 inhibitor.
    Ikeda Y
    Thromb Haemost; 1999 Aug; 82(2):435-8. PubMed ID: 10605734
    [No Abstract]   [Full Text] [Related]  

  • 33. Medical therapy for intermittent claudication.
    Rowlands TE; Donnelly R
    Eur J Vasc Endovasc Surg; 2007 Sep; 34(3):314-21. PubMed ID: 17532651
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication.
    Elam MB; Heckman J; Crouse JR; Hunninghake DB; Herd JA; Davidson M; Gordon IL; Bortey EB; Forbes WP
    Arterioscler Thromb Vasc Biol; 1998 Dec; 18(12):1942-7. PubMed ID: 9848888
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A preliminary study on the effects of exercising to maximum walking distance on platelet and endothelial function in patients with intermittent claudication.
    Collins P; Ford I; Ball D; Macaulay E; Greaves M; Brittenden J
    Eur J Vasc Endovasc Surg; 2006 Mar; 31(3):266-73. PubMed ID: 16360327
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cilostazol and dipyridamole synergistically inhibit human platelet aggregation.
    Liu Y; Cone J; Le SN; Fong M; Tao L; Shoaf SE; Bricmont P; Czerwiec FS; Kambayashi J; Yoshitake M; Sun B
    J Cardiovasc Pharmacol; 2004 Aug; 44(2):266-73. PubMed ID: 15243309
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A phase II dose-ranging study of the phosphodiesterase inhibitor K-134 in patients with peripheral artery disease and claudication.
    Brass EP; Cooper LT; Morgan RE; Hiatt WR
    J Vasc Surg; 2012 Feb; 55(2):381-389.e1. PubMed ID: 22119244
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prostaglandin E1 -containing nanoparticles improve walking activity in an experimental rat model of intermittent claudication.
    Ishihara T; Yamashita Y; Takasaki N; Yamamoto S; Hayashi E; Tahara K; Takenaga M; Yamakawa N; Ishihara T; Kasahara T; Mizushima T
    J Pharm Pharmacol; 2013 Aug; 65(8):1187-94. PubMed ID: 23837586
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cilostazol in intermittent claudication.
    Cariski AT; Lindmayer K
    Am J Health Syst Pharm; 2002 Jan; 59(1):81-2. PubMed ID: 11813475
    [No Abstract]   [Full Text] [Related]  

  • 40. Combination of Cilostazol and L-Carnitine Improves Walking Performance in Peripheral Arterial Disease Model Rats.
    Shiga T; Sahara H; Orito K
    Pharmacology; 2015; 96(5-6):210-6. PubMed ID: 26329263
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.